Human Monoclonal Antibody To Treat P. aeruginosa Infections in Cystic Fibrosis

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43DE022986-01A1
Agency Tracking Number: R43DE022986
Amount: $117,198.00
Phase: Phase I
Program: SBIR
Awards Year: 2013
Solicitation Year: 2013
Solicitation Topic Code: NIDCR
Solicitation Number: PA12-088
Small Business Information
442 SW UMATILLA AVE, STE 200, REDMOND, OR, 97756-7039
DUNS: 805599441
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 R SHIRTCLIFF
 (541) 504-3913
 mikes@advantagedental.com
Business Contact
 R SHIRTCLIFF
Phone: (541) 504-3913
Email: mikes@advantagedental.com
Research Institution
 Stub
Abstract
DESCRIPTION (provided by applicant): Topical fluorides have been the mainstay in the prevention of dental caries for decades. However, topical fluoride alone is not enough to thwart tooth decay in high-risk populations. The purpose of this Phase I application is to determine the technical and scientific feasibility of using a combination povidone-iodine (PVP-I)-5% sodium fluoride (NaF) varnish as a potential commercial product to prevent dental caries. The research will be conducted by the small business firm ADP Silver Dental Arrest, LLC, in collaboration with experienced researchers at the University of Washington Northwest Center to Reduce Oral Health Disparities. The Premier Dental Products Company will prepare the varnish to the specifications of the applicant at no cost to the grant. The Specific Aims of this Phase I SBIR are to: (1) Demonstrate that a new povidone iodine-sodium fluoride varnish has antimicrobial activity and fluoride bioavailability and enamel remineralization ability. (a) Use the in vitro moel developed by Castillo and colleagues to determine the bioavailability of fluoride and iodine release from an experimental povidone-iodine- sodium fluoride varnish; (b) Use an in vitro model of Tanzer and colleagues to assess the additive (indifferent), potentially synergistic, or potentially antagonistic effects of sodium fluoride and povidone-iodine against Streptococcus mutans using the criteria of Eliopoulos and Moellering; (c) Use a slight modification the Featherstone laboratory pH cycling model to test remineralization. (2) Assess the esthetic and organoleptic properties of the new povidone iodine-sodium fluoride varnish. Caries researchers for sometime have suggested strategies that combine an antiseptic with topical fluoride to reduce or eliminate the oral cariogenic bacteria reservoir in addition to topical fluoride which primarily remineralizes teeth enamel. Povidone-iodine is an FDA-approved and widely used bactericidal antiseptic. For the oral flora, iodine has preferential activities against streptococcl species. Moreover, iodine's effectiveness may last as long as six months. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: In this application we propose to: (1) use an in vitro model to determine the bioavailability of fluoride and iodine release from a povidone-iodine-sodium fluoride varnish; (2) use an in vitro model to assess the additive, potentially synergistic, or antagonistic effects of sodium fluoride and povidone-iodine against Streptococcus mutans, the primary pathogens in human dental caries; 3) use a pH cycling model to test remineralization; and 4) assess the organoleptic characteristics of test varnishes.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government